
The Uromigos
The UromigosAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 40 minutes
- Latest episode:
About this show
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Covers: oncology, genitourinary cancer, renal cell carcinoma, prostate cancer, bladder cancer, antibody drug conjugates, cancer immunotherapy, circulating tumor dna
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The Uromigos is a podcast on the latest developments in genitourinary cancer, hosted by Brian Rini and Tom Powles. Recent episodes cover T cell engagers in kidney cancer, doublet therapy in renal cell carcinoma, prostate cancer sequencing, and antibody drug conjugates and ctDNA in bladder cancer.
Cosmos
Similar in subject
- Oncology Brothers: Practice-Changing Cancer Discussions
Both cover: genitourinary cancer, oncology - Two Onc Docs
Both cover: prostate cancer, oncology
Similar shows
Explore more
Episodes
Uromigos Live 2026 – T Cell Engagers in RCC: Have We Finally Turned a Corner?
· 25 min
The final session of this year’s meeting discusses exciting T cell engager and CAR-T data from ESMO 2026. Are these approaches finally ready for prime time in mRCC?
Not rated yetUromigos Live 2026 – Are Doublets the New Standard of Care Throughout the RCC Continuum?
· 41 min
Doublet therapy has produced positive results in the adjuvant and refractory RCC settings. Are they the standard of care and what is the role of monotherapy for individual patients?
Not rated yetUromigos Live 2026 – Triplet Therapy in mRCC: What Went Wrong?
· 45 min
Recent attempts to build on the IO-doublet backbone in front-line clear cell RCC therapy have failed including LITESPARK-012. The panel discusses issues that have impacted these trials and where we go from here.
Not rated yetUromigos Live 2026 – Sequencing of Therapy Across the Continuum of Advanced Prostate Cancer
· 49 min
Several third agents added to the ADT/ARPI backbone in mHSPC have emerged in the last year including radioligands and PARP inhibitors. Navigating application to individual patients is discussed by our expert panel.
Not rated yetUromigos Live 2026 – High-risk Localized Prostate Cancer
· 48 min
Several phase 3 trials in high-risk localized prostate cancer have reported this year including PROTEUS and DASL. The panel debates if and how these will impact treatment of this patient population.
Not rated yetUromigos Live 2026 – MIBC: The Evolution of Antibody Drug Conjugates (ADCs) in Bladder Cancer
· 43 min
ADCs have become a mainstay of systemic therapy in bladder cancer. Where are we headed next? The panel discusses issues around target, payload and sequencing.
Not rated yetUromigos Live 2026 – MIBC: What is the necessity of bladder-directed therapy?
· 20 min
The emergence of highly active systemic therapy in the MIBC setting has challenged the notion that all patients need cystectomy or chemoradiation. Our live panel debates this thorny issue.
Not rated yetUromigos Live 2026 – MIBC: Does ctDNA and/or utDNA Have a Role?
· 29 min
The panel discusses emerging data on if and how ctDNA and urinary tumor DNA (utDNA) can be incorporated into prognostication and treatment decisions.
Not rated yetUromigos Live 2026 – MIBC: How Does VOLGA Change the Landscape?
· 44 min
The VOLGA trial was presented at ESMO 2026 and challenged the necessity of adjuvant therapy in MIBC. The panel discusses how these critical data impact the landscape.
Not rated yetUromigos Live 2026 – MIBC: What is the Role of Platinum-based Chemotherapy and/or Immune Therapy?
· 27 min
This kickoff session at this year’s live meeting looks at whether chemotherapy and immune therapy outside of EVP have a role in MIBC.
Not rated yetEpisode 530: ESMO 2026 Review
· 1 hr 0 min
Silke, Brian and Tom review exciting ESMO 2026 data in GU Oncology and more.
Not rated yetEpisode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
· 30 min
Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
Not rated yetEpisode 528: ESMO 2026 - LITESPARK 012
· 44 min
Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
Not rated yetEpisode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
· 38 min
Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
Not rated yetEpisode 526: ESMO 2026 - The VOLGA trial in MIBC
· 37 min
Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
Not rated yetEpisode 525: ESMO 2026 - PEACE-1 and CAPItello-281
· 46 min
Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC
Not rated yetEpisode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC
· 16 min
Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell transcription.
Not rated yetEpisode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
· 35 min
Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
Not rated yetEpisode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
· 24 min
Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.
Not rated yetEpisode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
· 32 min
Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.
Not rated yet